Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
about
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesEnhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling PathwaysLow-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signallingNew hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cellsAromatase resistance mechanisms in model systems in vivo.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausalFunctional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozoleThe Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerLoss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.Aromatase inhibitors and xenograft studies.Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitorsFluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathwayA role for estrogen receptor phosphorylation in the resistance to tamoxifen.Poor-prognosis estrogen receptor- positive disease: present and future clinical solutionsCordycepin induced MA-10 mouse Leydig tumor cell apoptosis by regulating p38 MAPKs and PI3K/AKT signaling pathwaysThe development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistanceBOLERO-2 - will this change practice in advanced breast cancer?SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studiesOestrogen-induced angiogenesis and implantation contribute to the development of parasitic myomas after laparoscopic morcellationHDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy.Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.Simultaneous targeting of estrogen receptor and HER2 in breast cancer.Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.Advances in mechanisms of resistance to aromatase inhibitors.Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?Sushi Domain-Containing Protein 3: A Potential Target for Breast Cancer.
P2860
Q26862550-1B6F5393-EB09-46D3-9058-BF2A9EE3627AQ28072897-058AD446-8C89-436C-AC90-084BB7D2890FQ28084585-78B7CF04-7BBE-4A3D-8209-D59E383DF0FDQ33658276-20CE16E8-447C-4B92-8AA9-39176E515F28Q33664216-8651F3A6-EC02-4454-9FC5-F6F9DB7744BEQ33700933-C4E86726-1066-4AEE-918D-C636938E2D2BQ33708119-944D4100-E350-4976-9CBF-BAE96B8B1B00Q33841512-B157392D-7508-4E04-B930-591639370257Q33928138-BE8A927C-3EA7-46E2-B0D2-79AF310085B4Q34589121-DA57C15D-21ED-429B-A845-E65DA8BBC0F7Q34611634-6B5AA038-86A5-4E76-AFF6-218194A62AF9Q34789970-24BE4C20-9B45-4A78-A691-3ECAB620FD11Q34956110-7954C93E-0E96-4558-B83F-6178E385D794Q34979662-1C53FBB3-F006-4550-8832-1A2274C46CCFQ35043020-7387A731-41D5-426A-B614-4A453CEFE3BDQ35091502-6DF2D53F-E848-4788-B2F7-C06A15C1D040Q35115629-D5F72DF0-FF3D-4BA4-8149-80882C8B6938Q35535547-005EF363-7C39-4ED1-9AF0-C82DCE5A80CFQ35684445-2DB5C134-842E-4DF6-B005-8698317B86A7Q35949291-FAADF029-F86F-4BAD-B7ED-66A103AA499EQ35992659-0C7C6B6E-1CA1-4C27-8BDF-559A30A8DF2FQ36013029-DB438E80-A818-4E3F-8277-8659A1862218Q36245315-4954A5C5-61E5-438F-9B9A-7D82D96F1300Q36413297-0F3683D1-B2DA-4248-BD53-90E369D574C1Q36512812-335B05D9-041F-4200-8A2F-C6FF6D796DABQ36517144-52C2AF8C-DEF6-4FCC-A6B2-C19C3820C5A9Q36589865-2C80C0F8-7F58-41F6-A39A-6097500C7E84Q36671906-FC6FBCC7-8887-4980-B5E2-24B830774449Q37025060-C02C2137-B4FE-47A8-9823-B5EC25418113Q37247518-F9EFCDA9-E120-4047-8A15-3958655B96D9Q37316692-077CEEA8-52BC-4BA3-927B-F3569757BBDCQ37381146-56528F6A-D136-43EE-A794-B0D602B38AADQ37401534-C8D7DFC5-A4D3-4A0A-99A0-8FE8EDBFFA3CQ37655166-1F258076-F195-4586-A939-7CB85A59F807Q37690655-A744C0C4-C296-4343-BDD0-4C8E997D40B2Q37782093-DEBC517C-1FFB-4795-ADC6-1FE72F5B79DFQ38004853-05548EDA-B475-4F3E-9C11-25582D16F6E2Q38190106-063B0D97-7E07-4943-9FC4-435BF9122E2AQ38262886-1B38CEE3-531A-422D-B66B-AF62902C63A4Q38306311-E40FED17-FF10-4413-84C0-DF870C186608
P2860
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@en
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@nl
type
label
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@en
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@nl
prefLabel
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@en
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@nl
P2093
P2860
P1433
P1476
Trastuzumab reverses letrozole ...... east cancer cells to estrogen.
@en
P2093
Adam Schayowitz
Angela Brodie
Luciana Macedo
Olga Goloubeva
P2860
P304
P356
10.1158/0008-5472.CAN-08-0857
P407
P577
2009-02-03T00:00:00Z